190 related articles for article (PubMed ID: 10348313)
1. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
Taylor-Robinson SD; Turjanski N; Bhattacharya S; Seery JP; Sargentoni J; Brooks DJ; Bryant DJ; Cox IJ
Metab Brain Dis; 1999 Mar; 14(1):45-55. PubMed ID: 10348313
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
Hou Z; Zhang Z; Meng H; Lin X; Sun B; Lei H; Fang K; Fang F; Liu M; Liu S
Int J Neurosci; 2014 Feb; 124(2):125-32. PubMed ID: 23931110
[TBL] [Abstract][Full Text] [Related]
3. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory.
Taylor-Robinson SD; Weeks RA; Bryant DJ; Sargentoni J; Marcus CD; Harding AE; Brooks DJ
Mov Disord; 1996 Mar; 11(2):167-73. PubMed ID: 8684387
[TBL] [Abstract][Full Text] [Related]
4. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
Ellis CM; Lemmens G; Williams SC; Simmons A; Dawson J; Leigh PN; Chaudhuri KR
Neurology; 1997 Aug; 49(2):438-44. PubMed ID: 9270574
[TBL] [Abstract][Full Text] [Related]
5. Cerebral diffusion tensor imaging and in vivo proton magnetic resonance spectroscopy in patients with fulminant hepatic failure.
Saksena S; Rai V; Saraswat VA; Rathore RS; Purwar A; Kumar M; Thomas MA; Gupta RK
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e111-9. PubMed ID: 17924951
[TBL] [Abstract][Full Text] [Related]
6. Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
Cruz CJ; Aminoff MJ; Meyerhoff DJ; Graham SH; Weiner MW
Magn Reson Imaging; 1997; 15(6):619-24. PubMed ID: 9285801
[TBL] [Abstract][Full Text] [Related]
7. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Kickler N; Krack P; Fraix V; Lebas JF; Lamalle L; Durif F; Krainik A; Rémy C; Segebarth C; Pollak P
NMR Biomed; 2007 Dec; 20(8):757-62. PubMed ID: 17334978
[TBL] [Abstract][Full Text] [Related]
8. MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
Zheng XN; Zhu XC; Ruan LX; Zhang LJ; Yuan M; Shang DS; Liu Y
J Zhejiang Univ Sci; 2004 Feb; 5(2):246-50. PubMed ID: 14674041
[TBL] [Abstract][Full Text] [Related]
9. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
Clarke CE; Lowry M; Horsman A
Mov Disord; 1997 May; 12(3):297-301. PubMed ID: 9159722
[TBL] [Abstract][Full Text] [Related]
10. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
Federico F; Simone IL; Lucivero V; De Mari M; Giannini P; Iliceto G; Mezzapesa DM; Lamberti P
J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):239-42. PubMed ID: 9069478
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Alterations Within the Primary Visual Cortex in Early Open-angle Glaucoma Patients: A Proton Magnetic Resonance Spectroscopy Study.
Guo L; Wang R; Tang Z; Sun X; Wu L; Wang J; Zhong Y; Xiao Z; Zhang Z
J Glaucoma; 2018 Dec; 27(12):1046-1051. PubMed ID: 30256276
[TBL] [Abstract][Full Text] [Related]
12. Striatal neuronal loss or dysfunction and choline rise in children with attention-deficit hyperactivity disorder: a 1H-magnetic resonance spectroscopy study.
Jin Z; Zang YF; Zeng YW; Zhang L; Wang YF
Neurosci Lett; 2001 Nov; 315(1-2):45-8. PubMed ID: 11711211
[TBL] [Abstract][Full Text] [Related]
13. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy.
Clarke CE; Lowry M
Eur J Neurol; 2000 Nov; 7(6):661-5. PubMed ID: 11136352
[TBL] [Abstract][Full Text] [Related]
14. Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS.
Garcia M; Huppertz HJ; Ziyeh S; Buechert M; Schumacher M; Mader I
Epilepsia; 2009 Mar; 50(3):486-92. PubMed ID: 19183221
[TBL] [Abstract][Full Text] [Related]
15. Myoinositol and glutamate complex neurometabolite abnormality after mild traumatic brain injury.
Kierans AS; Kirov II; Gonen O; Haemer G; Nisenbaum E; Babb JS; Grossman RI; Lui YW
Neurology; 2014 Feb; 82(6):521-8. PubMed ID: 24401686
[TBL] [Abstract][Full Text] [Related]
16. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
Tedeschi G; Litvan I; Bonavita S; Bertolino A; Lundbom N; Patronas NJ; Hallett M
Brain; 1997 Sep; 120 ( Pt 9)():1541-52. PubMed ID: 9313638
[TBL] [Abstract][Full Text] [Related]
17. Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Podell M; Hadjiconstantinou M; Smith MA; Neff NH
Exp Neurol; 2003 Feb; 179(2):159-66. PubMed ID: 12618122
[TBL] [Abstract][Full Text] [Related]
18. Positive correlations between cerebral choline and renal dysfunction in chronic renal failure.
Sasaki O; Hattori N; Nakahama H; Inoue N; Nakamura S; Inenaga T; Kohno S; Sawada T; Kawano Y
Neuroradiology; 2006 May; 48(5):300-6. PubMed ID: 16586119
[TBL] [Abstract][Full Text] [Related]
19. Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1H MRS) in children with Down syndrome.
Śmigielska-Kuzia J; Boćkowski L; Sobaniec W; Kułak W; Sendrowski K
Pharmacol Rep; 2010; 62(6):1070-7. PubMed ID: 21273664
[TBL] [Abstract][Full Text] [Related]
20. Proton MRS in acute traumatic brain injury: role for glutamate/glutamine and choline for outcome prediction.
Shutter L; Tong KA; Holshouser BA
J Neurotrauma; 2004 Dec; 21(12):1693-705. PubMed ID: 15684761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
